Dosing & Uses
Dosage Forms & Strengths
tablet: Schedule II
Short-term (generally less than 10 days) management of acute pain
Lowest effective dose for the shortest duration consistent with individual patient treatment goals
Usual dose: 5-7.5 mg/200 mg PO q4-6 hr PRN; not to exceed 5 tabs/24hr
Not recommended in patients with advanced renal disease
Renal disease or impairment; increased risk of renal toxicity and injury may occur
Not indicated for the treatment of chronic conditions such as osteoarthritis or rheumatoid arthritis
Extra caution and reduced dosages should be used when treating the elderly
Elderly or debilitated patients may experience increased risk of gastrointestinal injury, including fatal events; increased risk of renal toxicity and injury; respiratory depression
Dosage Forms & Strengths
tablet: Schedule II
<16 years: Safety and efficacy not established
- Short-term (generally <10 days) management of acute pain
- Lowest effective dose for the shortest duration consistent with individual patient treatment goals
- Usual dose: 5-7.5 mg/200 mg PO q4-6 hr PRN; not to exceed 5 tabs/24hr
Serious - Use Alternative
Significant - Monitor Closely
Agitation, depression, dizziness, dysphoria, euphoria
Faintness, mental clouding, restlessness, sedation, weakness
Flushing, sweating, urticaria
Headache, fatigue, lightheadedness, tinnitus
Erythematous macular rashes
Erythema multiforme, exfoliative dermatitis, toxic epidermal necrolysis, photosensitivity
GI bleeding, GI ulceration
Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia
Acute renal failure, decreased creatinine clearance, elevations in BUN
Black Box Warnings
- NSAIDs may increase risk of serious cardiovascular thrombotic events, myocardial infarction (MI), and stroke, which can be fatal
- Risk may increase with duration of use
- Patients with risk factors for or existing cardiovascular disease may be at greater risk
- NSAIDs are contraindicated for perioperative pain in the setting of coronary artery bypass graft (CABG) surgery (increased risk of MI & stroke)
- NSAIDs increase risk of serious GI adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal
- GI adverse events may occur at any time during use and without warning symptoms
- Elderly patients are at greater risk for serious GI events
Coronary artery bypass graft (CABG) surgery, treatment of peri-operative pain; increased incidence of myocardial infarction and stroke
Hypersensitivity to ibuprofen, hydrocodone
Hypersensitivity to other opioids; cross-sensitivity reaction possible
Relative: bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, SLE, ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus), asthma, urticaria, or allergic-type reactions following aspirin or other nonsteroidal anti-inflammatory agents; severe, even fatal, anaphylactic-like reactions
Cardiovascular event risk may increase w/ duration of use
Gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal may occur
Abuse, misuse, diversion, and dependence potential
Addison's disease; respiratory depression may occur
Alcohol use or smoking; increased risk of gastrointestinal injury
Asthma, especially with history of aspirin-sensitive asthma; severe bronchospasm and fatalities may occur
Coagulation disorder; bleeding time may be prolonged
Long-term use; increased risk of gastrointestinal or renal injury; anemia may occur
Pregnancy, third trimester use; premature close of ductus arteriosus may occur
Skin reactions; serious adverse events including exfoliative dermatitis, Stevens Johnson syndrome, toxic epidermal necrolysis
Pregnancy & Lactation
Pregnancy Category: C; D in 3rd trimester
Lactation: Excreted in breast milk; not recommended
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Hydrocodone: Binds to opiate receptors in the CNS, which in turn produces generalized CNS depression and alters perception and response to pain
Ibuprofen: Inhibits synthesis of prostaglandins in body tissues by inhibiting cyclooxygenase; at least 2 isoenzymes, cyclooxygenase-1 (COX-1) & -2 (COX-2); has antipyretic, anti-inflammatory, and analgesic properties
Hydrocodone: by liver (O-demethylation, N-demethylation, 6-keto reduction); hepatic P450 enzyme CYP2D6
Ibuprofen: rapid hepatic oxidation to inactive metabolites: (+)-2-[4'-(2-hydroxy-2-methylpropyl) phenyl] propionic acid (metabolite A), (+)-2-[4'-(2-carboxypropyl) phenyl] propionic acid (metabolite B)
- Hydrocodone: Mainly urine
- Ibuprofen: Urine 50-60% (<10% unchanged)
- Hydrocodone: 3.3-4.4 hr
- Ibuprofen: 2-4 hr
Onset: 0.5 hr (ibuprofen)
Bioavailability 80-90% (ibuprofen)
Vd: 0.12 L/kg (ibuprofen)
Protein Bound: 90-99% (ibuprofen)
Peak Plasma Time
- Hydrocodone: 1.3 hr
- Ibuprofen: 2 hr
- Hydrocodone: 4-8 hr
- Ibuprofen: 4-6 hr
Hydrocodone is metabolized to Hydromorphone via CYP2D6; CYP2D6 poor metabolizers may not achieve adequate analgesia
Ultra-rapid metabolizers (up to 7% of Caucasians and up to 30% of Asian and African populations) may have increased toxicity due to rapid conversion
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.